Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Biotage Board/Management Information 2024

Feb 15, 2024

2894_rns_2024-02-15_4ffa35a3-6b49-4ff8-abbc-8f6dbbb7f699.pdf

Board/Management Information

Open in viewer

Opens in your device viewer

Biotage appoints Andrew Kellett as CFO

Andrew Kellett was appointed Interim CFO of Biotage on 11 September 2023. Andrew has been offered and accepted to take on the role as permanent CFO of Biotage. The appointment is effective as of today's date and he becomes part of the group management.

"We are really pleased to welcome Andrew to the permanent position as CFO of Biotage. During his interim appointment we have seen good proof of his qualities, and I am looking forward to work with Andrew." says Torben Jørgensen, Interim CEO & President, Biotage.

Contacts

Torben Jörgensen, Interim President & CEO Tel: +46-707 49 05 84, [email protected]

About Biotage

Biotage is the Global Go-To Separations Company, supporting customers from drug discovery and development through to diagnostics and analytical testing with intelligent and sustainable workflow solutions. Our expertise and top-tier separation solutions play a key role in streamlining our customers' workflows and improving their outcomes.

Headquartered in Sweden, Biotage operates globally with 700 employees, serving over 80 countries. Our company is listed on NASDAQ Stockholm (BIOT). Website: www.biotage.com

Attachments

Biotage appoints Andrew Kellett as CFO